Acura begins clinical trial of meth-resistant Nexafed extended-release formulations

Acura Pharmaceuticals has started a pilot clinical trial of two experimental formulations of Nexafed (pseudoephedrine HCl) extended-release tablets using the company's second generation methamphetamine resistant technology, IMPEDE 2.0.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news